PFF Summit 2019 Professional Sessions
Thursday > Sessions
Community Pulmonologists and ILD Fellows
 | Anoop M. Nambiar, MD, MS: Welcome |
| Lisa Lancaster, MD: Practical approach to the evaluation of ILD | VIEW SLIDES |
| Mridu Gulati, MD: Environmental links to ILD | VIEW SLIDES |
| Jonathan Kropski, MD: Genetics of ILD | VIEW SLIDES |
Santiago Restrepo, MD: Use of HRCT in ILD and IPF | This presentation is currently embargoed | |
| Fayez Kheir, MD: Lung biopsy: transbronchial, cryobiopsy, and surgical | VIEW SLIDES |
| Ganesh Raghu, MD: New IPF Diagnostic Guidelines: Fleischner vs. ATS | VIEW SLIDES |
| Tessy Paul, MD: What’s new in CTD-ILDs? | VIEW SLIDES |
| Mary Beth Scholand, MD: Pharmacologic therapies for IPF | VIEW SLIDES |
| Kathleen Lindell, PhD, RN: Patient-Focused Management for the ILD Patient | VIEW SLIDES |
| Steve Nathan, MD: PH-ILD: does treatment improve outcomes? | VIEW SLIDES |
| Deborah Levine, MD: Patient-focused management for the ILD patient | VIEW SLIDES |
| Joao A. de Andrade, MD, Ayodeji Adegunsoye, MD, Joyce Johnson, MD, Steve Nathan, MD, Ganesh Raghu, MD, and Santiago Restrepo, MD: Interesting cases & multidisciplinary team simulation | VIEW SLIDES |
Nurses and Allied Health Network
| Pauline Bianchi, RN, BSN: Welcome |
| Carolyn Spada, RN, BSN & Jennifer Hayes, RN, BSN: Overview of ILD | VIEW SLIDES |
| Wendi Mason, MSN, RN, ACNP-BC : ILD Diagnosis | VIEW SLIDES |
| Anne Turner, RN4, BSN, JD : Challenges of ILD Management: Drug Therapy | VIEW SLIDES |
| Susan Jacobs, RN, MS: Challenges of ILD Management: Oxygen| VIEW SLIDES |
| Karen S. Van Kerkhove, BSN, RN: Challenges of ILD Management: Pulmonary Rehab | VIEW SLIDES |
| Julie A. Porcelli, RN, MSN, CNL: Challenges of ILD Management: Management of Comorbidity| VIEW SLIDES |
| Rebekah Edwards, DNP, FNP-C : Challenges of ILD Management:Lung Transplant | VIEW SLIDES |
| Kathleen Lindell, PhD, RN, ATSF, FAAN: Challenges of ILD Management: Palliative Care | VIEW SLIDES |
| Lori Flint, RN, BSN & Janell Reichuber, RN, BSN: Successful Management Strategies | VIEW SLIDES |
| Pauline Bianchi, RN, BSN: PFF Updates | VIEW SLIDES |
Friday > Sessions
Keynote Address
| Edith Perez, MD: Translational Genomics: The Future is Now | VIEW SLIDES |
Plenary Session I
LEADERS: Greg Cosgrove, MD and Christine Kim Garcia, MD
| Christine Kim Garcia, MD: Impact of telomere length and mutations on treatment and transplant responses in pulmonary fibrosis | VIEW SLIDES |
| Naftali Kaminski, MD: Cell-based precision medicine approaches to pulmonary fibrosis – Insight from the IPF Cell Atlas | VIEW SLIDES |
| Imre Noth, MD: Integration of genetic information in clinical trial design for precision medicine | VIEW SLIDES |
| Panel Q&A |
Senescence
LEADERS: David Lynch, MB
| Nicolas Musi, MD: The role of senescence in driving the pathology of aging-related diseases | VIEW SLIDES |
| Melanie Koenigshoff, MD, PhD: What cells in the IPF lung are senescent and why does it matter? | VIEW SLIDES |
| Cory Hogaboam, PhD: The effects of senolytics in animal models of PF | VIEW SLIDES |
| Anoop M. Nambiar, MD, MS: Senolytics put to the test for IPF in a clinical trial | VIEW SLIDES |
Clinical Trials Innovation Series
| Craig S. Conoscenti, MD, FCCP, ATSF: Boehringer Ingelheim | VIEW SLIDES |
Genentech | This presentation is currently not available. | |
FibroGen | This presentation is currently not available. | |
| Paul Ford, MD, PhD: Galapagos | VIEW SLIDES |
| Sangeeta Bhorade, MD: Veracyte | VIEW SLIDES |
Pulmonary Fibrosis Registries and Resources: What is in Them, What Have We Learned, and Where are We Going
LEADERS: Andrew Limper, MD and Kevin Flaherty, MD
| Samuel Ash, MD: Quantitative Imaging of Interstitial Abnormalities | VIEW SLIDES |
| Kevin Flaherty, MD, MS: Pulmonary Fibrosis Foundation Patient Registry | VIEW SLIDES |
| Dan Culver, DO: Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO)| VIEW SLIDES |
| Andreas Günther, MD: The European IPF Registry (eurIPFreg) | VIEW SLIDES |
| Toby Maher, MD: PROFILE-IPF | VIEW SLIDES |
| Panel Discussion |
IPF Diagnostics
Leaders: David Lynch, MB and Joseph Lasky, MD
| Jonathan Chung, MD : Updated HRCT Diagnostic Categories: Rationale for the Change | VIEW SLIDES |
| Stephen Humphries, PhD : New HRCT Quantitative Methods to Enhance Trial Design and Clinical Assessment | VIEW SLIDES |
| Majid Shafiq, MD : Cryobiopsy for ILD Diagnosis: Is it Dime for a Sea-Change? | VIEW SLIDES |
| Joseph Lasky, MD : Where do Genomic Classifiers Fit into the Pathway for ILD Diagnosis? | VIEW SLIDES |
| IPF Diagnostics Q&A |
Networking Dinner
| Networking Dinner and Honoring Ceremony |
> Sessions
Keynote Address
| Bray Patrick-Lake : Clinical Trials: Empowering Patients to Participate | VIEW SLIDES |
Plenary Session II
LEADERS: Ayodeji Adegunsoye, MD & Justin Oldham, MD
| Jeffrey Swigris, DO: Clinician Perspective: Importance of Patient-Related Outcomes | VIEW SLIDES |
| Ganesh Raghu, MD: Is the Time Right for Changes in PF Clinical Trial Endpoints? | Slides are not available at this time |
| Greg Cosgrove, MD & Dave Sherry: Patient Perspective |
| Panel Discussion and Audience Q&A |
Transcriptomics
LEADERS: Naftali Kaminski, MD & Antje Prasse, MD
| Milica Vukmirovic, PhD: The Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis | VIEW SLIDES |
| Oliver Eickelberg, MD: Insights into the Pathobiology of IPF from Single Cell Transcriptomics| VIEW SLIDES |
| Antje Prasse, MD: BAL Gene Expression as an Indicator of Outcome and Disease Mechanisms in IPF| VIEW SLIDES |
Clinical Trials Innovation Series
| Aryeh Fischer, MD: Bristol-Myers Squibb | VIEW SLIDES |
| Jaye Bea Smalley and Zoran Popmihajlov, MD: Celgene | VIEW SLIDES |
| Sanjeev Khindri, MD, MRCP: Galecto | VIEW SLIDES |
| Eduard Gorina, MD: Pliant Therapeutics| VIEW SLIDES |
| Ahmet Tutuncu, MD, PhD: Respivant | VIEW SLIDES |
Autoimmune ILD and Chronic Hypersensitivity Pneumonitis (CHP) – Nuances and similarities
LEADERS: Patricia Sime, MD & Mary Strek, MD
| Robert Guzy, MD: Fibroblast Growth Factors in Bleomycin-induced Pulmonary Fibrosis | VIEW SLIDES |
| Ivan Rosas, MD: Rheumatoid lung: Informing treatment of primary and inflammatory fibrosis by understanding the pathogenesis of RAILD | VIEW SLIDES |
| Mary Strek, MD: Advances in Scleroderma-ILD | VIEW SLIDES |
| Sonye Danoff, MD & Justin Oldham, MD: Is IPAF really an entity unto its own: Pro/Con | VIEW DANOFF SLIDES | VIEW OLDHAM SLIDES |
| Evans Fernandez Perez, MD, MS: CHP: have we made progress addressing the knowledge gaps in diagnosis and treatment? | VIEW SLIDES |
| Autoimmune ILD and Chronic Hypersensitivity Pneumonitis (CHP) Q&A |
Therapeutic Challenges and Controversies in ILD
LEADERS: Harold R. Collard, MD
| Harold R. Collard, MD: How Should We Approach GERD in ILD/IPF now? | VIEW SLIDES |
| Steve Nathan, MD: PH-ILD: past studies and future directions | VIEW SLIDES |
| Joao A. de Andrade, MD: Should Unclassifiable ILD be Treated like IPF? | VIEW SLIDES |
| Kevin Flaherty, MD, MS: Progressive fibrotic ILD: will anti-fibrotics be a “one-size-fits-all” treatment? | VIEW SLIDES |
SPONSORS
Diamond Level
Gold Level
Silver Level
